Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshimitsu Fujii

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Journal of Gastroenterology|June 23, 2023
Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional studyKatsuyoshi Matsuoka, Hajime Yamazaki, Masakazu Nagahori, et al.
Journal of Gastroenterology and Hepatology|November 1, 2017
Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's diseaseHiroki Tanaka, Noriko Kamata, Akihiro Yamada, et al.
Journal of Crohn'S & Colitis|October 5, 2023
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 TrialMarc Ferrante, Peter M Irving, Maria T Abreu, et al.
Journal of Gastroenterology and Hepatology|October 1, 2020
Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysisMotoi Uchino, Hiroki Ikeuchi, Keisuke Hata, et al.
Intestinal Research|June 4, 2025
The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective studyTaku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, et al.
Digestive Diseases and Sciences|April 7, 2020
Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy OutcomesChikako Watanabe, Masakazu Nagahori, Toshimitsu Fujii, et al.
Intestinal Research|July 14, 2025
Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational studyTaku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, et al.
Journal of Gastroenterology and Hepatology|January 15, 2021
Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysisTakeo Yoshihara, Shinichiro Shinzaki, Takahiro Amano, et al.
Journal of Gastroenterology and Hepatology|September 1, 2020
Intestinal cancer in patients with Crohn's disease: A systematic review and meta-analysisMotoi Uchino, Hiroki Ikeuchi, Keisuke Hata, et al.
Inflammatory Bowel Diseases|October 31, 2017
Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort StudyTaku Kobayashi, Asahi Hishida, Hiroki Tanaka, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Journal of Gastroenterology|June 23, 2023
Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional studyKatsuyoshi Matsuoka, Hajime Yamazaki, Masakazu Nagahori, et al.
Journal of Gastroenterology and Hepatology|November 1, 2017
Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's diseaseHiroki Tanaka, Noriko Kamata, Akihiro Yamada, et al.
Journal of Crohn'S & Colitis|October 5, 2023
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 TrialMarc Ferrante, Peter M Irving, Maria T Abreu, et al.
Journal of Gastroenterology and Hepatology|October 1, 2020
Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysisMotoi Uchino, Hiroki Ikeuchi, Keisuke Hata, et al.
Intestinal Research|June 4, 2025
The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective studyTaku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, et al.
Digestive Diseases and Sciences|April 7, 2020
Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy OutcomesChikako Watanabe, Masakazu Nagahori, Toshimitsu Fujii, et al.
Intestinal Research|July 14, 2025
Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational studyTaku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, et al.
Journal of Gastroenterology and Hepatology|January 15, 2021
Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysisTakeo Yoshihara, Shinichiro Shinzaki, Takahiro Amano, et al.
Journal of Gastroenterology and Hepatology|September 1, 2020
Intestinal cancer in patients with Crohn's disease: A systematic review and meta-analysisMotoi Uchino, Hiroki Ikeuchi, Keisuke Hata, et al.
Inflammatory Bowel Diseases|October 31, 2017
Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort StudyTaku Kobayashi, Asahi Hishida, Hiroki Tanaka, et al.
Pageof 9